HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer

详细信息    查看全文

• 作者：Yao Wang ; MD^a ; ^b ; ¹ ; Mingxun Li ; MD^b ; ¹ ; Fanling Meng ; MD ; PhD^a ; ^{dr_mfl1979@126.com} ; Ge Lou ; MD ; PhD^a ; ^{doctorlouge@126.com}
• 关键词：HPIP ; Immunohistochemistry ; Epithelial ovarian cancer ; Platinum resistance
• 刊名：Human Pathology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：60
• 期：Complete
• 页码：114-120
• 全文大小：846 K
• 卷排序：60

文摘

This study aims to investigate the expression of the hematopoietic pre&ndash;B-cell leukemia transcription factor&ndash;interacting protein (HPIP) and its association with platinum resistance in epithelial ovarian cancer (EOC). The protein expression of HPIP was analyzed by immunohistochemistry in 248 patients with EOC. Furthermore, we analyzed the association between HPIP expression and clinicopathological features including prognosis in EOC samples. High HPIP expression was correlated with platinum resistance in EOCs. HPIP in platinum-resistant cases was overexpressed compared with that in platinum-sensitive cases (P < .001). Platinum resistance was independently correlated with the International Federation of Gynecology and Obstetrics stage and HPIP overexpression. High HPIP expression was positively correlated with International Federation of Gynecology and Obstetrics stage, histologic grade, residual tumor size, lymph node metastasis, serum levels of CA125, and poor prognosis. Our findings indicate that HPIP overexpression is an independent predictor of platinum-based chemotherapy resistance and that it may also be a potential biomarker for targeted therapy.